Report : Europe Quantitative Structure-Activity Relationship Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Application (Drug Discovery, Molecular Modelling, Chemical Screening, Regulatory and Decision-Making, and Others); Industry (Pharmaceuticals, Cosmetics, Environmental, and Food & Beverage)
Drug Discovery Segment has the Largest Share of Application in the Europe Quantitative Structure-Activity Relationship Market during 2020–2027
According to a new market research study on “Europe Quantitative Structure-Activity Relationship Market to 2027 – COVID-19 Impact and Regional Analysis and Forecast by Application, and Industry,” is expected to reach US$ 512.4 million by 2027 from US$ 401.9 million in 2020. The market is estimated to grow at a CAGR of 3.5% from 2020 to 2027. The report provides trends prevailing in the Europe quantitative structure-activity relationship market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increasing adoption of modelling tools in drug discovery and increasing economic burden of drug discovery. However, the market is expected experiencing slow growth during the forecast period owing to the less adoption in emerging countries.
Computational Modeling has uses in the battle against Covid-19 beyond analyzing the structure of the virus itself. French artificial intelligence start-up Exact Cure is seeking to model and predict the efficacy and pharmacokinetics of already approved drugs being studied for Covid-19. Exact Cure has started to simulate two drugs being repurposed for Covid-19 to date: anti-malarial hydroxychloroquine and lopinavir/ritonavir, a protease inhibitor combination indicated for HIV. However, the start-up is building on this work through a recent partnership with analytics company Elsevier to leverage its PharmaPendium database of US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval documents to allow state-of-the-art models for 20 drugs and the integration of more personal parameters. The initiatives of governments in the region open a window of opportunities for the firms involved in the quantitative structure-activity relationship market.
The market for quantitative structure-activity relationship market is segmented into application and industry. The quantitative structure-activity relationship market based on application is segmented into drug discovery, molecular modelling, chemical screening, regulatory and decision-making, and other applications. In 2019, the drug discovery accounted for the largest share and is expected to grow faster during the forecast period as it often involves the use of QSAR to identify chemical structures that could have good inhibitory effects on specific targets and have low toxicity (non-specific activity). Of special interest is the prediction of partition coefficient log P, which is an important measure used in identifying "drug likeness" according to Lipinski's Rule of Five. Moreover, companies have collaborated with pharmaceutical companies to speed up the drug discovery and development.
ProtoQSAR SL, Intertek Group Plc, Laboratory Corporation of America Holdings, Dassault Systems SE, Bibra Toxicology Advice & Consulting Ltd, and QSAR LAB SP. Z O are among the leading companies in the Europe quantitative structure-activity relationship market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in November 2020, Novartis has received a global license to Mesoblast’s quantitative structure-activity relationship (QSAR) Remestemcel-L in the treatment of COVID-19. The deal lands Mesoblast $50 million upfront and a partner's support that could help address critical quality attribute concerns raised by the FDA.
The market for quantitative structure-activity relationship market is segmented into application and industry. Based on application, the quantitative structure-activity relationship market is segmented into drug discovery, molecular modelling, chemical screening, regulatory and decision-making, and other applications. Based on end user, the quantitative structure-activity relationship market is segmented into pharmaceuticals, cosmetics, environmental, and food & beverage. Geographically, the quantitative structure-activity relationship market is segmented into Europe (Germany, UK, France, Spain, Italy, Rest of Europe).